Interview with Sam Kamali, CEO of Myonerv
Myonerv is developing a new approach to stroke rehabilitation that aims to expand access to intensive, effective therapy beyond the clinic. Following their recent win at the Innovator’s Pitch Challenge at RESI London, the team is advancing a wearable neurotechnology designed to help patients regain upper-limb movement through intention-driven stimulation and remote clinical support. We spoke with Myonerv to learn more about the problem they are addressing, their technology, and what comes next as they move toward clinical trials and global partnerships.
 Sam Kamali |
 Caitlin Dolegowski |
Caitlin Dolegowski (CD): For readers who may be new to Myonerv, how do you describe the company’s mission and core technology?
Sam Kamali (SK): Myonerv is a breakthrough British neurotechnology solution designed to transform stroke rehabilitation through an active, remote-operated wearable medical device that restores movement in patients with post-stroke upper-limb paralysis (paresis). A wearable, non-invasive neurostimulator that helps retrain movement after stroke by detecting a patient’s intention to move and delivering targeted electrical stimulation to augment that movement. This “closed-loop” approach is supported by scientific evidence showing that synchronising stimulation with a person’s voluntary effort can enhance neuroplasticity – the brain’s ability to rewire and relearn lost movements.
Unlike traditional electrical stimulators, Myonerv uses flexible bioelectronic materials to create soft, reusable electrodes that conform comfortably to the arm. The system is designed to be lightweight, easy to apply, and suitable for both clinical and home environments. It will also allow therapists to monitor progress and support patients remotely, helping expand rehabilitation capacity without increasing staff burden.
CD: What problem are you addressing, and why is now the right time for your approach?
SK: Partial paralysis after a Stroke affects 70% of all survivors, approximately 900,000 new patients annually in the UK, DACH and USA. Despite clear evidence that intensive, early, and consistent rehabilitation improves outcomes, most patients in the UK receive only 45 minutes of therapy per day in hospital and as little as 1 hour per week after discharge – far below nationally recommended 3 hours per day. We believe the resulting “plateau” in stroke recovery is not biological, but due to the lack of therapy access and intensity.
Myonerv directly addresses this challenge by developing a first-in-class wearable, closed-loop neurostimulator that enables continuous, intention-driven rehabilitation both in-clinic and at home. It combines bioelectronic sensing, software-assisted control loops, reusable polymer electrodes and remote therapist connectivity (capabilities not currently available in NHS or international markets). The innovation advances beyond the state of the art in its miniaturisation, accuracy, sustainability, and ability to extend clinical rehabilitation into the community setting.
CD: What stood out most to you about competing in—and winning—the Innovator’s Pitch Challenge at RESI London?
SK: “It’s so refreshing to hear such a good pitch, after such a long time”. These were the words that stuck with us from our judge, Soyoung Park, General Partner at 1004 Ventures.
This echoed the depth of excitement from investors throughout the event. The judges and audience deeply understood both the clinical problem and the commercial challenge of scaling medical technologies within healthcare systems. People were enthusiastic about the prospect of a remote-controlled rehabilitation device that can exponentially increase the amount of therapy received by patients. Winning wasn’t just validation of the technology - it was validation of the need and our ability to change the state of healthcare worldwide.
CD: How has the exposure from RESI London impacted conversations with investors or strategic partners so far?
SK: RESI London has materially accelerated conversations. Since the event, we’ve seen increased inbound interest from international investors and strategic partners across Europe and the US, particularly those focused on neurotechnology, digital health, and rehabilitation.
The win has acted as a strong credibility signal – shortening diligence cycles and shifting discussions toward clinical milestones, regulatory strategy, and partnership structures rather than basic validation. It has also opened doors to potential manufacturing and healthcare delivery partners who see Myonerv as an international platform, not just a single product.
CD: Where is Myonerv currently in terms of fundraising or partnership strategy?
SK: We have officially opened a £2 million pre-seed priced round. Our strategy is to combine the £215k in non-dilutive funding with targeted private investment to de-risk the technology before scaling. What is promising is that we are receiving non-dilutive funding faster than we can announce it, with a recent admission into the Founders Factory x Innovate UK (Hospital to Home) Biomedical Catalyst Accelerator, which enables a£100k grant for us to perform our first in-patient trials.
This touches on our recent partnership arrangements, as we are working closely with several patient networks and the Cambridgeshire & Peterborough Foundation Trust (CPFT), an NHS Trust overseeing hospital networks across the East of England. CPFT has agreed to sponsor our clinical trials, which fast-tracks the process for trial approvals, recruitment and secure documentation of data. CPFT has shown great enthusiasm in being our first pilot sites for Myonerv. This is only a small part of our partnership arrangements, as we have several more with other hospitals across the UK who have given us Letters of Interest to give Myonerv to 1,200 patients per year once the device is available in the market.
We are now looking to build on the network we have built in Cambridge thanks to the £120k grant won from ARIA as part of Cambridge NeuroWorks, tasked with developing a first-in-class scalable neural interface for the world. Our next step is to visit RESI JPM in San Francisco on January 12th 2026 to create more partnerships with the US network as we look to expand our reach globally.
CD: What milestones are you most focused on over the next 12–18 months?
SK: Our primary focus is delivering on the tech. We are currently finalizing our functional prototype with the Manufacturing Technology Centre, a major UK-based factory, to test on participants with approvals from the University of Cambridge. Our shiny new prototype will be ready in time for an exciting Myonerv demo at RESI Europe in Lisbon, on 23rd March 2026!
We are then looking to build on this to develop a TRL6/7 alpha device and completing a feasibility clinical study in stroke survivors. In parallel, we are advancing our regulatory pathway, quality management systems, and health-economic evidence to support adoption by healthcare providers. Having secured regulatory and commercial partners who will help navigate our pathway through into international markets.
We are simultaneously focused on strengthening manufacturing readiness, expanding our clinical and patient engagement network, and closing our pre-seed round. Together, these milestones position Myonerv for scale - clinically, commercially, and globally.
| Apply to Pitch at RESI Europe 2026 |
Laura Vivian
NeuroHope is developing a 
Bilix is a clinical-stage biotechnology company developing synthetic PEGylated bilirubin nanoparticles for organ protection and inflammatory injury. Its lead program targets ischemia reperfusion injury by addressing oxidative stress, ferroptosis, and immune dysregulation following surgery and transplantation, with completed Phase 1 clinical testing and an ongoing Phase 2a study in cardiac surgery-associated acute kidney injury.
Oncovita is developing MVdeltaC, an intratumoral measles virus-based oncolytic immunotherapy designed to convert immunologically cold solid tumors into targets the immune system can recognize and eliminate. By engineering a clinically familiar measles backbone with a C protein deletion, MVdeltaC drives potent immunogenic cell death and reshapes the tumor microenvironment, making previously hidden tumors visible to the immune system, much as PET imaging made occult disease visible to clinicians. Initial programs focus on pleural mesothelioma, with a clear strategy to expand into additional solid tumors such as triple-negative breast cancer.
Adaptyx is developing a continuous biomolecular monitoring platform designed to bring clarity to cortisol-driven disease. By enabling real-time measurement of cortisol dynamics, the company addresses a central blind spot in endocrinology: current diagnostics rely on static snapshots of a hormone that fluctuates throughout the day, which could change how conditions such as Cushing’s, Addison’s, and related disorders are diagnosed and managed.
Cureage is a rare disease-focused biotechnology company developing first-in-class therapeutics for Neurofibromatosis Type 1 and related disorders. The company targets the underlying biology driving tumor formation and disease progression in NF1, an area of significant unmet need. It works closely with the Children’s Tumor Foundation, reflecting deep alignment with the patient and clinical community.
Qnity is a deep-tech life sciences company that applies quantum-electrochemical sensing to transform molecular screening and drug discovery. Its platform delivers ultra-sensitive, real-time measurements of molecular binding across a wide range of molecule types, enabling researchers and developers to identify and characterize interactions with greater precision and throughput than traditional methods like SPR or ELISA.
iQure is developing a new class of treatments for brain disorders by restoring balance to glutamate, a key neurotransmitter that becomes toxic when dysregulated. What makes their technology unique is its focus on astrocytes—support cells in the brain—by enhancing the activity of EAAT2, the main transporter responsible for clearing excess glutamate.
HiRO is a global clinical research organization that supports emerging and established biotech companies in designing and executing clinical development programs across Asia Pacific and other regions. Beyond trial execution, HiRO works closely with clients to determine the most effective geography and sequencing strategy for each program, balancing regulatory pathways, patient access, cost, speed, and downstream partnering objectives. By helping companies deploy trials thoughtfully across markets such as Japan, Korea, Taiwan, Australia, Southeast Asia, and China, HiRO reduces geographic and execution risk early in development.
Qualisure Diagnostics develops RNA-based classifiers that guide treatment decisions in thyroid cancer. Unlike tests focused solely on diagnosis, Qualisure’s assays inform post-diagnosis management. Clinical guideline citations support them, and the company has achieved international adoption through a decentralized deployment model.
Alterna Therapeutics develops RNA-targeted drugs designed to correct harmful cellular miscommunication driving disease. The company applies deep splicing biology to genetic and oncology indications with high unmet need, leveraging a platform with the potential to generate multiple differentiated assets over time.
Next Phase Newsletter 